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Here, we present evidence for a specific role of the splicing-related factor TCERG1 in regu-
lating apoptosis in live cells by modulating the alternative splicing of the apoptotic genes
Bcl-x and Fas. We show that TCERG1 modulates Bcl-x alternative splicing during apopto-
sis and its activity in Bcl-x alternative splicing correlates with the induction of apoptosis, as
determined by assessing dead cells, sub-G1-phase cells, annexin-V binding, cell viability,
and cleavage of caspase-3 and PARP-1. Furthermore, the effect of TCERG1 on apoptosis
involved changes in mitochondrial membrane permeabilization. We also found that deple-
tion of TCERG1 reduces the expression of the activated form of the pro-apoptotic mitochon-
drial membrane protein Bak, which remains inactive by heterodimerizing with Bcl-xL,
preventing the initial step of cytochrome c release in Bak-mediated mitochondrial apoptosis.
In addition, we provide evidence that TCERG1 also participates in the death receptor-medi-
ated apoptosis pathway. Interestingly, TCERG1 also modulates Fas/CD95 alternative splic-
ing. We propose that TCERG1 sensitizes a cell to apoptotic agents, thus promoting
apoptosis by regulating the alternative splicing of both the Bcl-x and Fas/CD95 genes. Our
findings may provide a new link between the control of alternative splicing and the molecular
events leading to apoptosis.
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Introduction
It is estimated that more than 90% of multiexonic human genes undergo alternative splicing,
resulting in a widespread tool to achieve proteomic diversity [1, 2]. Alternative splicing plays
an important role in gene expression regulation that underlies numerous physiological pro-
cesses, such as neuronal signaling, stress responses, and apoptosis [3–5]. Changes in the cis- or
trans-regulation of this process can cause multiple pathologies as a result of general or specific
aberrant pre-mRNA processing, underscoring the fundamental importance of this regulatory
process [6].
Apoptosis is one form of programmed cell death required for proper development and
homeostasis in multicellular organisms [7, 8]. Dysregulation of this process could also result in
pathological alterations, such as neurodegenerative disorders, autoimmune diseases, or cancer
[9–11]. There are two main apoptosis pathways: the intrinsic, or mitochondrial, pathway and
the extrinsic, or death receptor, pathway. A large number of genes involved in both pathways
are regulated by alternative splicing, allowing the production of distinct protein isoforms,
which often differ in function, from one common messenger RNA precursor (pre-mRNA). For
example, the death receptor Fas/CD95, which encodes a transmembrane death receptor, can be
alternatively processed, excluding exon 6 from the mRNA transcript to produce a soluble iso-
form that inhibits apoptosis [12, 13]. Several genes of the Bcl-2 family are also regulated via
alternative splicing to generate proteins with opposite functions in cell death. The equilibrium
between anti-apoptotic and pro-apoptotic isoforms is essential for death or survival decisions
[14].
The best characterized example of this equilibrium is Bcl-x, which belongs to the Bcl-2 fam-
ily and is alternatively spliced to produce anti-apoptotic long (Bcl-xL) and pro-apoptotic short
(Bcl-xS) isoforms [15]. Bcl-xL is widely expressed and present at high levels in oncogenic tis-
sues. Overexpression of Bcl-xL confers resistance to apoptotic stimuli and chemotherapeutic
agents, favoring metastasis [15, 16]. Bcl-xS is primarily expressed in lymph nodes, thymus,
ovary, and other tissues that require an elevated rate of cell replacement [17]. Bcl-xS induces
cell death and sensitizes several cell types to apoptotic agents, although whether this protein
plays a direct or indirect role in this process remains controversial [18–21]. Bcl-xL plays a key
role in apoptosis by preventing cytochrome c release from the mitochondria into the cytosol
through a number of diverse protein-protein interactions [22]. However, the mechanism by
which Bcl-2 proteins provoke apoptosis is still under debate [23]. Consistent with a potential
model for this mechanism, the pro-apoptotic Bax and Bak proteins remain blocked in healthy
cells by anti-apoptotic proteins, such as Bcl-xL [24]. Upon apoptotic induction, other Bcl2 fam-
ily members disrupt these interactions, thereby displacing Bax and/or Bak from Bcl-xL and
other anti-apoptotic proteins, allowing them to be activated by self-oligomerization. In this
model, the ratio between Bcl-xL and Bcl-xS isoforms is important to maintain the critical inter-
actions that can lead to cell health or death. The mechanism by which the ratio between both
Bcl-x isoforms is regulated, resulting in the expression of the Bcl-xL isoform, which prevents
Bax and/or Bak from activating apoptosis, remains unknown.
The two Bcl-x isoforms are generated from two alternative 5’ splice sites (ss) located in exon
2 of the pre-mRNA. Several cis-elements present in Bcl-x pre-mRNA and RNA-binding pro-
teins recognizing these elements regulate the alternative splicing of Bcl-x [25–29]. The physio-
logical relevance of these interactions that lead to specific changes in the alternative splicing of
Bcl-x has been demonstrated in several studies. Staurosporine, a general kinase inhibitor and
inducer of the intrinsic pathway of apoptosis, switches the production of Bcl-x toward the Bcl-
xS isoform by interfering with the protein kinase C (PKC) signaling pathway through a
361-nucleotide region (SB1) on the Bcl-x pre-mRNA that is located upstream of the Bcl-x 5’ ss
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[28]. Similarly, ceramide and protein phosphatase-1, which are regulators of apoptosis, modu-
late the use of Bcl-x 5’ ss by dephosphorylating members of the SR family of splicing proteins
[30, 31]. Because the fine-tuned balance between Bcl-xL and Bcl-xS is important for cell survival
or death, modulation of Bcl-x alternative splicing is considered useful for new therapeutic
developments in apoptosis-related diseases [32–34].
Recently, we showed that the elongation and splicing-related factor TCERG1 regulates the
alternative splicing of Bcl-x by modulating the rate of RNA polymerase II (RNAPII) transcrip-
tion [35]. These results together with previous reports implicating TCERG1 in the regulation
of apoptosis [36, 37] suggest a role for TCERG1 in the regulation of cell death. TCERG1 is a
nuclear protein that contains multiple protein domains, notably the three WW domains in the
amino-terminus and the six FF repeat domains in the carboxyl-terminus [38]. TCERG1 associ-
ates with hyperphosphorylated RNAPII and transcriptional elongation and splicing compo-
nents through both the WW and FF domains [37, 39–41]. Given these and other functional
data showing the effects of TCERG1 on the alternative splicing of reporter minigene constructs
[42–44], TCERG1 has been proposed as a potential factor in coordinating transcriptional elon-
gation and splicing. Consistent with this hypothesis, we recently demonstrated that TCERG1
increases the rate of RNAPII transcription of Bcl-x in vivo to promote the splicing of the pro-
apoptotic Bcl-xS isoform via the SB1 regulatory element in exon 2 of Bcl-x [35]. This result
underscores the importance of the functional coupling between transcription and alternative
splicing in the regulation of gene expression, particularly for Bcl-x [45]. Given these data, it was
of interest to investigate whether the effect of TCERG1 on the alternative splicing of Bcl-x has
functional consequences for apoptosis. Here, we investigate the role of TCERG1 in apoptosis
and report that TCERG1 affects both the intrinsic and extrinsic apoptosis pathways. We pro-
pose that TCERG1 sensitizes the cell to apoptotic agents, thereby promoting apoptosis by regu-
lating the alternative splicing of the apoptotic genes Bcl-x and Fas/CD95.
Materials and Methods
Cell cultures and treatments
HEK293T and HeLa cells (American Type Culture Collection) were grown in Dulbecco’s mod-
ified Eagle Medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS) (Gibco) supple-
mented with penicillin (100 U)/streptomycin (0.1 mg/ml) (Lonza,), and 4 mM L-glutamine
(Gibco). The GFP (control) and TCERG1-knocked down T-Rex-HEK293T cell lines have been
described previously [46]. The cells were maintained in high-glucose DMEM containing 10%
FBS supplemented with penicillin/streptomycin and L-glutamine. We used 200 μg/ml hygro-
mycin (Invitrogen) for selection, 5 μg/ml tetracycline (Sigma) for shRNA induction, and 15 μg/
ml blasticidin (Invitrogen) for the inhibition of tetracycline induction. Jurkat cells stably trans-
fected with pGeneClip-shTCERG1-C1 (Jurkat shTCERG1-C1) or Jurkat shTCERG1-(1-3-4)
have been described previously [46]. The cells were grown in RPMI 1640 medium (BioWhit-
taker) containing 10% fetal calf serum (PAN Biotech GmbH) and supplemented with 2 mM L-
glutamine, 100 μg/ml streptomycin, 100 U/ml penicillin, and 5 μg/ml puromycin (Invitrogen)
at 37°C. For induction of the intrinsic apoptosis pathway, staurosporine (Sigma) was used at
1 μM for 12 h in T-Rex-HEK293T cells and 0.5 μM for 1 h in Jurkat cells, unless otherwise
indicated.
Peripheral blood mononuclear cells (PBMCs) were isolated from blood of healthy donors
by centrifugation through a Ficoll-Hypaque gradient (GE Healthcare, Milwaukee, WI) and cul-
tured in the same conditions as Jurkat cells. PBMCs were activated by treatment with 5μg/ml
PHA (Sigma-Aldrich, St. Louis, MO) and 300 units/ml IL-2 (Chiron, Emeryville, CA).
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Plasmids
The pEFBOST7-TCERG1 plasmid has been described previously [41, 47]. pcDNA3-FLAG-
Bcl-xS was generated by subcloning the cDNA of the Bcl-xS isoform into the pcDNA3-FLAG
vector by standard PCR using the following oligonucleotides: BclEcoRI-F, 5’-GGGGAATTCT
CATTTCCGACTGAAG-3’, and BclXbaI-R, 5’-GGGGAATTCTCATTTCCGACTGAAG-3’.
Transfection assays
Jurkat cells were transfected by electroporation with an EasyJet Plus Electroporator (Equibio).
In brief, 5 x 106 cells were collected in 350 μl of RPMI without supplementation and mixed
with 5 μg of plasmid DNA in an electroporation cuvette with a 4 mm electrode gap (Equibio).
The cells were transfected by one pulse at 280 V and 1500 μF. After transfection, the cells were
incubated in supplemented RPMI for 48 h at 37°C. Then, the cells were treated as indicated
and processed for analysis. In each transfection, the plasmid pCDNA3-GFP was included to
evaluate the transfection efficiency, which was approximately 60–75%.
Resting PBMCs were transiently transfected with the Easyjet Plus Electroporator. In brief,
107 PBMCs were collected in 350μl of RPMI without supplement and mixed with 1μg/106 cells
of plasmid DNA. Cells were transfected in a cuvette with 4mm electrode gap, at 320V, 1500μF
and maximum resistance. After transfection, cells were incubated in supplemental RPMI for
18h, at 37°C. For flow cytometry, an in-house developed monoclonal antibody against
TCERG1 and a secondary antibody conjugated to Alexa 633 (Molecular Probes, Eugene, OR)
were used. pEYFP-C1 vector was used as control of transfection.
RNA extraction and reverse transcription (RT)-PCR analysis
Total RNA was extracted from cells with peqGOLD TriFast (peQlab) according to the manufac-
turer’s protocol. The RNA was digested with 10 U of RNase-free DNase (Roche) for 30 min at
37°C. After DNase treatment at 70°C for 5 min, 1 μg of endogenous RNA or 400 ng of plasmid-
derived RNA was reverse-transcribed using oligo(dT)15 and Moloney murine leukemia virus
reverse transcriptase (Invitrogen) for 1 h at 37°C. One-tenth of the resulting cDNA was ampli-
fied by PCR using the following oligonucleotides: X3, 5’-ATGGCAGCAGTAAAGCA AGCG-3’,
and X2, 5’-TCATTTCCGACTGAAGAGTGA-3’, for endogenous Bcl-x detection; Fend-F, 5’-
GCACCAAATGTGAACATGG-3’, and Fend-R, 5’-CCATTCTTTCGAACAAA GCC-3’, for
endogenous Fas isoforms. After 30 cycles at 60°C, the products were separated on a 2% agarose
gel and the intensity of the bands was quantified using Quantity One software (Bio-Rad). The
quantification of the transcripts isoform of Fas/CD95 was performed by real-time PCR using
the iTaq Universal SYBR Green Supermix and the iCycler thermal station (Bio-Rad) with the
following oligonucleotides: FasE6, 5’-TAACTTGGGGTGGCTTTGTC-3’, and FasE7, 5’-
TCCTTTCTGTGCTTTCTGCAT-3’, for the long pro-apoptotic isoform; and FasE5E7, 5’-
CAAAGAGGAAGTGAAGAGAAA-3’ and FasE7Rev, 5’-AGGATTTAAAGTTGGAGATTCA-3’,
for the short anti-apoptotic isoform. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as an internal gene control and amplified with the oligonucleotides GAPDH-F, 5’-
ATGGGGAAGGTGAAGGTCG-3’, and GAPDH-R, 5’- GGGTCATTGATGGCAACAATATC-3’.
The values are represented as (E Fas)ΔCT Fas/(E GAPDH)ΔCT GAPDH, where E is the PCR effi-
ciency and ΔCT = (the cycle threshold [CT] for control cells)—(CT for TCERG1 knockdown).
Western blot analysis
A fraction of the cells were lysed in cold T7 buffer (20 mMHEPES [pH 7.9], 150 mM NaCl, 5
mM EDTA, 1% NP-40, 1 mM dithiothreitol, protease inhibitor mixture [Complete, Roche],
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and 1 mM PMSF). The proteins were separated by 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), transferred to a nitrocellulose membrane (Amersham Biosci-
ences), and then incubated with specific antibodies against TCERG1 [41] at 1:2000 and CDK9
(sc-484, Santa Cruz Biotechnology) at 1:1000. Peroxidase-conjugated secondary antibodies
(PerkinElmer Life Science) were used at a 1:5000 dilution, and the bound antibodies were
detected by enhanced chemiluminescence (PerkinElmer Life Science). The apoptosis proteins
were separated by 12.5% SDS-PAGE, transferred to nitrocellulose membranes, and detected
using antibodies against caspase-3 (sc-7148), cleaved Parp-1 (sc-56196), Bcl-xL (sc-23958), and
Bcl-2 (sc-7382) (Santa Cruz Biotechnology) at 1:500 dilution and β-actin (A5441, Sigma) at
1:5000. A densitometric analysis was performed using ImageJ software. The gel bands were
quantified, and the background noise was subtracted from the images. The relative ratio of
optical density units was calculated relative to the gel band corresponding to the internal con-
trol (β-actin) for each lane and each type of sample. The p20+p17/procaspase-3 ratio was cal-
culated to determine the values of the caspase isoforms.
Cell cycle
Approximately 1 x 106 Jurkat cells were collected in polystyrene tubes and washed twice with
phosphate-buffered saline (PBS). The cells were fixed with 70% ethanol at 4°C for at least 15
min. After washing with PBS, the cells were diluted in a solution of PBS containing 100 μg/ml
RNase (Roche) and 40 μg/ml propidium iodide (PI, Sigma). After incubating for 20 minutes at
37°C, the samples were analyzed using a FACSCalibur flow cytometer (BD Biosciences, Clon-
tech). The cell cycle data were analyzed using the FlowJo v7.6.5 software.
Annexin-V binding assays
Approximately 1 x 106 cells were stained with annexin-V conjugated to fluorescein isothiocya-
nate (FITC) or phycoerythrin (Immunostep S.L.); fluorescence was measured by flow cytome-
try. The data were analyzed using CellQuest software.
Active caspase-3 and caspase-8 measurement
The quantification of active caspase-3 and caspase-8 was performed using the Caspase-Glo 3/7
and the Caspase-Glo 8 assays (Promega) according to the manufacturer’s instructions. The
luminescent signal (relative light units, RLUs), which was directly proportional to caspase acti-
vation, was measured using an Infinite F200 TECAN Luminometer. The data were normalized
to the protein concentration measured by the Bradford assay.
Cell viability
Cell viability was determined using the CellTiter-Glo1 Luminescent Cell Viability Assay (Pro-
mega), following the manufacturer’s instructions. Briefly, 1 x 105 cells were harvested by centri-
fugation, washed twice with 1X PBS, and diluted in lysis buffer. After incubation for 10 min at
room temperature to stabilize the luminescent signal, the cell lysates were deposited in an
opaque-walled multiwell plate and analyzed using an Infinite F200 TECAN Luminometer. The
data were normalized to the protein concentration measured by the Bradford assay.
Mitochondrial membrane potential gradient (ΔΨm)
ΔCm was measured using the Mitochondrial Staining JC-1 Assay Kit (Sigma) according to the
manufacturer’s instructions. Briefly, 1.5 x 106 Jurkat cells were incubated with JC-1 (5,5’,6,6’-
tetrachloro-1,1’,3,3’-tetraethylbenzimidazolylcarbocyanine iodide) staining solution, and both
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green and red fluorescence were measured in the FL1 and FL2 channels, respectively, by flow
cytometry. Mitochondrial depolarization was calculated by measuring the green fluorescence
intensity.
Analysis of intracellular Bak expression
Bak-specific immunofluorescence was analyzed after treatment with 1μM staurosporine for 3
h. Cells were fixed in 1% paraformaldehyde (PFA) for 1 h. After washing with 1X PBS, the cells
were permeabilized with 1% Tween-20 in 1X PBS and then incubated with a Bak primary anti-
body (AM03, Calbiochem) and a secondary antibody conjugated to FITC. The analysis was
performed using a FACSCalibur flow cytometer (BD Biosciences Clontech) with CellQuest
software.
Mitochondrial cytochrome c release
The release of cytochrome c from the mitochondrial intermembrane space into the cytosol was
measured using InnoCyte Flow Cytometric Cytochrome c Release Kit (Calbiochem). Briefly, 5
x 106 cells were treated or not with 1μM staurosporine for 3 h, permeabilized, and then fixed
with 1% PFA in 1X PBS. After staining with a monoclonal antibody against cytochrome c
obtained from Calbiochem (Merck Chemicals Ltd., Nottingham, UK) and a secondary anti-
body conjugated to FITC, cytochrome c release was measured by flow cytometry. The release
of cytochrome c into the cytosol was also analyzed by fluorescence microscopy. Living cells
treated or not with staurosporine were adhered to PolyPrep slides (Sigma-Aldrich) and fixed
with 2% PFA. Immunofluorescence assays were then performed as previously described [48]
using the antibody against cytochrome c. Images were obtained with a Leica DMI 4000B
Inverted Microscope (Leica Microsystems, Barcelona, Spain).
Statistical analysis
The statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software
Inc., San Diego, CA). Two-tailed Student’s t-tests and Mann-Whitney U-test analysis were
used to compare means between the samples and their respective controls. The p values are
represented by asterisks (, p< 0.05; , p< 0.01). The absence of an asterisk indicates that the
change relative to the control was not statistically significant.
Results
TCERG1modifies the Bcl-x splicing pattern upon staurosporine-
mediated apoptosis induction
We conducted in vivo assays to determine whether TCERG1 influences apoptosis. First, we
analyzed the effect of TCERG1 knockdown on Bcl-x alternative splicing during apoptosis. Bcl-
x proteins are involved in the mitochondrial pathway of apoptosis; therefore, we used stauros-
porine, a protein kinase inhibitor that mainly induces the mitochondrial death pathway. We
analyzed the splicing pattern of Bcl-x after 12 h of 1 μM staurosporine treatment by RT-PCR in
T-Rex-HEK293T cells, in which the expression of control shRNA or shRNA targeting
TCERG1 was induced by the addition of tetracycline. In control cells, we observed an increase
of Bcl-xS and a decrease of Bcl-xL (Fig 1B, lanes 1 and 3), as reported previously [28]. This pat-
tern was partially reversed upon TCERG1 knockdown (Fig 1B, lanes 2 and 4). To perform this
protocol under optimal conditions, we used Jurkat cells, which have been extensively used to
study apoptotic gene modulation. We used stable TCERG1-knocked down Jurkat cells to ana-
lyze the splicing pattern of Bcl-x upon staurosporine treatment by RT-PCR. Similar to previous
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results, addition of staurosporine produced the Bcl-xS isoform almost exclusively (Fig 1C, lanes
1 and 3). We observed a shift in the Bcl-x splicing pattern toward the Bcl-xL isoform upon
TCERG1 depletion more clearly evident in the staurosporine-treated Jurkat cells (Fig 1C, lanes
2 and 4). The analysis of cell lysates showed that the T-Rex-HEK293T and Jurkat cells with
TCERG1 knockdown expressed significantly lower amounts of TCERG1 protein than the con-
trol cells (Fig 1B and 1C, bottom). Taken together, these data indicate that TCERG1 modulates
Bcl-x alternative splicing during apoptosis.
Fig 1. Regulation ofBcl-x alternative splicing by TCERG1 upon staurosporine-induced apoptosis. (A)
Schematic representation of the structure of the Bcl-x gene, with exons (boxes) and introns (lines). Two
splice variants derived from the Bcl-x gene, anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS, are generated via
alternative 5’ splice site (XS and XL) selection within exon 2. The dotted lines indicate the alternative splicing
events. (B and C) Knockdown of TCERG1 (KD) increased the level of the anti-apoptotic Bcl-xL isoform after
staurosporine treatment. Control (lanes 1 and 3) and TCERG1 knockdown T-Rex-HEK293T cells (lanes 2
and 4) (B) and Jurkat cells (C) were treated with 1 μM staurosporine for 12 h and 0.5 μM staurosporine for 1 h,
respectively. After total RNA extraction, the RNA splicing variants were amplified by RT-PCR, and the
products were separated on 2% agarose gels. The graphs show the densitometric results as the percentage
of the Bcl-xL isoform in three independent experiments (means ± SEM). *, p < 0.05, **, p < 0.01. A fraction of
the cell lysates was analyzed by immunoblotting for TCERG1, CDK9, and ß-actin.
doi:10.1371/journal.pone.0139812.g001
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TCERG1 depletion decreases the proportion of apoptotic cells induced
by staurosporine
As a first approach to investigate the relevant biological consequences for the regulation of Bcl-
x alternative splicing by TCERG1, we measured the percentage of dead Jurkat-shTCERG1 cells
upon staurosporine treatment using propidium iodide (PI) (Fig 2A and 2B). Because PI does
not enter unfixed live cells, it is commonly used to detect dead cells in a given population.
However, this technique does not distinguish between apoptotic and necrotic cells. To better
quantify the apoptotic cells, we discarded the cell population with a higher amount of PI,
which is thought to constitute the necrotic cells (Fig 2A and 2B, marker M2), from the calcula-
tion of total cell death (Fig 2A and 2B, marker M1). We examined the sensitivity of Jurkat cells
to different concentrations of staurosporine and observed a dose-dependent effect (Fig 2A).
We then analyzed the effect of this treatment on the Jurkat-shTCERG1 cells in the presence of
0.5 mM staurosporine. After 1 h of staurosporine treatment, the cells were analyzed by flow
cytometry to evaluate PI staining as a measure of cell death. We found that TCERG1 knock-
down reduced the number of apoptotic cells (Fig 2B). To corroborate these data, we performed
cell cycle experiments to determine the number of cells in the sub-G1 phase and reveal the dis-
continuous fragmentation of nuclear DNA during apoptosis, corresponding to apoptotic cells.
In the absence of staurosporine treatment, there was no significant difference in the percentage
of cells in the sub-G1 population between control and TCERG1-knocked down cells (Fig 2C,
-STAU). After apoptotic induction, an increase in sub-G1 phase formation was observed in
both Jurkat cell lines. Interestingly, the percentage of cells in the sub-G1 population was signifi-
cantly lower in TCERG1-knocked down cells compared with control cells (Fig 2C, +STAU).
Moreover, transient overexpression of TCERG1 in TCERG1-knocked down cells almost
completely recovered the percentage of cells in sub-G1 phase upon staurosporine induction to
the level observed in control cells, indicating that the effect observed in the decrease of sub-G1
cells was mainly due to the TCERG1 depletion (Fig 2C). The other phases of the cell cycle were
not significantly altered (Fig 2D). To lend additional support to our data, we also performed
annexin-V binding assays. Annexin-V specifically binds phosphatidylserine when this mole-
cule is located at the cell surface under apoptotic conditions. After staurosporine induction, we
measured the number of annexin-V-positive cells by flow cytometry in our Jurkat cell lines. In
agreement with the above data, we observed significantly reduced annexin-positive cells upon
TCERG1 knockdown (Fig 2E). Finally, we performed experiments to determine the number of
viable cells based on the quantification of the ATP present as an indicator of metabolically
active cells. We observed that the knockdown of TCERG1 partially recovered the decrease in
cell viability in response to staurosporine (Fig 2F). These findings indicate that TCERG1 deple-
tion reverses the effect of staurosporine-induced apoptosis.
To demonstrate the physiological relevance of TCERG1 in apoptosis in non-transformed
cells, we performed experiments using resting PBMCs isolated from healthy donors. PBMCs
were transfected with pGeneClip-shTCERG1-(1-3-4) vectors (rate 1:1:1) or the negative con-
trol pGeneClip-shTCERG1-C1, and the pEYFP vector was co-transfected as control of trans-
fection efficiency. Cells were incubated for 3 days with PHA/IL-2 and then split and treated or
not with staurosporine 10 μM for 3 h. Early apoptosis was measured in EYFP+ cells by flow
cytometry after staining with annexin V. Apoptosis induced by staurosporine was reduced
1.8-fold in TCERG1 knockdown cells, compared to control cells (Fig 3A). The level of expres-
sion of TCERG1 was analyzed by flow cytometry using a specific monoclonal antibody and a
secondary antibody conjugated to Alexa 633. TCERG1 expression was reduced approximately
2-fold in TCERG1 knockdown cells (Fig 3B).
TCERG1 Affects Apoptosis
PLOS ONE | DOI:10.1371/journal.pone.0139812 October 13, 2015 8 / 24
Fig 2. Effect of TCERG1 knockdown on the staurosporine-induced apoptotic pathway. (A) Effect of staurosporine treatment on Jurkat cells. Flow
cytometry analysis of Jurkat cells stained with PI without (black) or with the addition of 0.25 (red) or 0.5 μM staurosporine (blue) for 1 h. M1: marker line
representing the percentage of dead cells. M2: marker line indicating the population of necrotic cells. The histogram of flow cytometry and bar graphs of the
percentage of M1 and M1-M2 cells are shown. The graphs show the data from three independent experiments (means ± SEM). (B) Depletion of TCERG1
decreases the percentage of total cell death. Jurkat cells with control or stable TCERG1mRNA interference (TCERG1 KD) were stained with PI without
(black) or with the addition of 0.5 μM staurosporine for 1 h (red). The histogram of flow cytometry and bar graphs of the percentage of M1 and M1-M2 cells are
shown. The graph shows the data from three independent experiments (means ± SEM). *, p < 0.05. (C) Depletion of TCERG1 decreases the percentage of
TCERG1 Affects Apoptosis
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Reduction of apoptosis by TCERG1 depletion is associated with a
decrease in active caspase-3
Caspase-3 activity is currently used as a marker of apoptosis. To measure active caspase-3 in
the cells, we used an assay based on the addition of a luciferase substrate that is cleaved in the
presence of active caspase-3, leading to a luminescent signal. The number of luciferase units
directly correlates with the amount of active caspase-3 present in the cell. We treated the cells
with staurosporine and observed a more than 6-fold increase in the quantity of active caspase-
3 in control cells, whereas in the TCERG1 knockdown cells, this increase was significantly
lower (Fig 4A). Caspase-3 is expressed as a 35 kDa inactive precursor from which the 17 kDa
(p17) and 11 kDa (p11) subunits are proteolytically generated during apoptosis. The caspase-3
precursor is first cleaved to generate a p11 subunit and a p20 peptide, which is subsequently
cleaved to produce the mature p17 subunit. The active caspase-3 enzyme is a hetero-tetramer
composed of two p17 peptides and two p11 subunits. Using specific antibodies against caspase-
3, we observed significantly less p20 and p17 upon TCERG1 knockdown (Fig 4B, compare lane
2 to lane 4). The cleavage of the caspase-3 target protein PARP-1 was also analyzed as a marker
of caspase activity. PARP-1 is cleaved during apoptosis leading to the appearance of an 89 kDa
product. Using an antibody specific for the cleaved protein, we observed that PARP-1 cleavage
was reduced upon TCERG1 knockdown (Fig 4B, compare lane 2 to lane 4). These findings con-
firm that in cells treated with staurosporine, the inhibition of TCERG1 causes a decrease in cas-
pase-3 activation.
TCERG1 promotes changes in mitochondrial membrane
permeabilization and in the emergence of the active form of Bak upon
apoptosis induction
During apoptosis, a cascade of key events occurs in the mitochondria, including the dissipation
of the mitochondrial membrane potential gradient (ΔCm). ΔCm is a parameter of mitochon-
drial function and therefore a suitable indicator of cell death. To monitor mitochondrial health,
we used the membrane-permeable JC-1 dye. In healthy cells, the dye is incorporated into the
mitochondria, spontaneously forming red-fluorescent JC-1 aggregates. In apoptotic cells, the
dissipation of the gradient favors the diffusion of the dye, resulting in green-fluorescent JC-1
monomers. We measured the fluorescence emission in control and TCERG1-depleted cells by
flow cytometry. We observed a loss of green monomer fluorescence upon TCERG1 knock-
down in staurosporine-treated cells, indicating a higher ΔCm (Fig 5A). This finding suggests
that TCERG1 affects the mitochondrial membrane potential in the early stages of programmed
cell death caused by staurosporine treatment.
To test wether other apoptotic inducers are able to elicit a similar response as that observed
for staurosporine, we used doxorubicin and oxaliplatin. Doxorubicin induces DNA damage
the sub-G1 cell population. Jurkat cells were transiently transfected with control or the siTCERG1 alone (TCERG1 KD) or with a TCERG1 expression plasmid
(TCERG1 KD + TCERG1OE). The graph shows the percentage of cells in the sub-G1 phase of the cell cycle in the absence (-STAU) or presence (+STAU)
of 0.5 μM staurosporine for 1 h. Data are from four independent experiments (means ± SEM). *, p < 0.05. (D) Cell cycle distribution of stably transfected
Jurkat cells. Jurkat cells with control or stable TCERG1mRNA interference (TCERG1 KD) were transiently transfected with an empty vector or, in the case of
TCERG1 KD, with a TCERG1 expression vector (TCERG1OE). After 48 h, the cells were incubated in the absence (-STAU) or presence of staurosporine
(+STAU) at 0.5 μM for 1 h. The cells were fixed and incubated with PI. The cell cycle stages were analyzed by flow cytometry. The graph shows the
percentage of cells in each phase of the cell cycle. Data are from three independent experiments (means ± SEM). *, p < 0.05. (E) TCERG1 knockdown
reduces annexin-V binding after staurosporine treatment. Control and TCERG1 knockdown (KD) Jurkat cells were incubated with annexin-V and analyzed
by flow cytometry in the absence (-STAU) or in the presence of 0.5 μM staurosporine (+STAU) for 1 h. The bar graph shows the percentage of annexin-V-
positive cells from three independent experiments (means ± SEM). *, p < 0.05. (F) TCERG1 knockdown increases the viability of staurosporine-treated cells.
Control and TCERG1-knockdown Jurkat cells were incubated without (-STAU) or with 0.5 μM staurosporine (+STAU) for 1 h, and viability was measured by
chemiluminescence. The bar graph represents the percentage of viable cells (means ± SEM). Data are from four independent experiments. **, p < 0.01.
doi:10.1371/journal.pone.0139812.g002
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through topoisomerase II inhibition and free radical generation via a redox reaction [49], and
the DNA damage-inducer oxaliplatin favors the pro-apoptotic Bcl-xS variant [50]. We did not
observe differences in the percentage of dead Jurkat-shTCERG1 and control cells upon doxo-
rubicin treatment using PI, whereas we did find that TCERG1 knockdown reduced the per-
centage of dead cells upon oxaliplatin treatment (data not shown). Moreover, we observed a
loss of green monomer fluorescence upon TCERG1 knockdown in oxaliplatin-treated cells,
indicating a higher ΔCm (Fig 5B). Interestingly, the signaling routes elicited by staurosporine
and oxaliplatin appear to converge into the same splicing regulatory event controlling the pro-
duction of the pro-apoptotic Bcl-xS [51] (see Discussion).
Fig 3. Effect of TCERG1 on apoptosis using PBMCs. (A) Transiently reduced expression of TCERG1 in
PBMCs decreases apoptosis induced by staurosporine. Apoptosis induced by staurosporine was measured
by flow cytometry in EYFP+ PBMCs transiently transfected with pGeneClip-shTCERG1-(1-3-4) or control
vectors after staining with annexin-V-PE. We performed the experiment three independent times. (B) Level of
TCERG1 expression was analyzed by flow cytometry.
doi:10.1371/journal.pone.0139812.g003
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The Bcl-2 family member Bak is an integral mitochondrial membrane protein that exposes
an amino-terminal-occluded epitope upon apoptosis induction with staurosporine or other sti-
muli [52]. This conformational change converts Bak into a primed state and provokes the for-
mation of higher-order Bak homo-oligomers that are thought to be responsible for the
mitochondrial dysfunctions that characterize the commitment of a cell to apoptosis, such as
cytochrome c release. Bak binds to Bcl-xL, and this heterodimerization may prevent the cells
from undergoing apoptotic death [52–56]. To investigate the mechanisms underlying the
effects of TCERG1 on apoptosis, we measured the change in Bak-associated immunofluores-
cence by flow cytometry using an antibody specific for the amino-terminal-occluded epitope of
Bak [52]. Interestingly, we observed reduced appearance of Bak amino-terminal-associated
immunofluorescence in the shTCERG1 cells (Fig 5C), indicating that the cells were less per-
turbed or damaged upon TCERG1 depletion. The release of cytochrome c from Jurkat cells
upon staurosporine treatment was also analyzed by flow cytometry (Fig 5D) and immunofluo-
rescence (Fig 5E). The results showed a decrease in cytochrome c release in shTCERG1 cells
than control cells. Together, these data show that upon staurosporine induction, TCERG1
knockdown reduces the availability of the amino-terminus of Bak and prevents the initial step
of cytochrome c release under Bak-mediated mitochondrial apoptosis.
The effect of TCERG1 on staurosporine-mediated apoptosis involves
changes in the Bcl-xL/Bcl-xS ratio
As Bcl-x plays a role in maintaining the mitochondrial membrane potential [57], we deter-
mined whether the effect of TCERG1 on ΔCm is caused by a change in the level of Bcl-xL and
Bcl-xS isoforms through alternative splicing regulation. The Bcl-xL isoform produces an anti-
apoptotic protein that prevents mitochondrial apoptosis [58]. However, although the Bcl-xS
Fig 4. Analysis of caspase-3 activation in TCERG1-depleted cells after staurosporine induction. (A)
Activation of caspase-3 was decreased in TCERG1-knockdown Jurkat cells treated with staurosporine.
Caspase-3 activation was measured by chemiluminescence in control and TCERG1-knockdown Jurkat cells
treated (+STAU) or not with 0.5 μM staurosporine (-STAU) for 1 h. The bar diagram shows the fold activation
from four independent experiments (means ± SEM). Data obtained from cells without staurosporine were set
as 1. *, p < 0.05. (B) Analysis of TCERG1, procaspase-3 cleavage (precursor p35 and cleaved fragments
p20/p17), and PARP-1 cleavage (p89) levels. Protein expression was analyzed by immunoblotting using
specific antibodies in protein extracts obtained from control and TCERG1-knockdown Jurkat cells treated
(+STAU) or not with 0.5 μM staurosporine (-STAU) for 1 h. ß-actin was used as a loading control. The
quantification of the bands is shown below each panel.
doi:10.1371/journal.pone.0139812.g004
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protein favors apoptosis, it is not clear whether this protein is sufficient to directly antagonize
the anti-apoptotic effects of Bcl-2 and Bcl-xL [15] or whether it plays a secondary role in sensi-
tizing cells to pro-apoptotic agents [18, 19]. To determine whether Bcl-xS favors apoptosis in
Jurkat cells, we transiently transfected a plasmid expressing this isoform and analyzed the cell
cycle by flow cytometry. We observed a slight increase in the sub-G1 cell population upon Bcl-
xS overexpression in the absence of staurosporine, and this effect was statistically significant
Fig 5. Effect of TCERG1 on staurosporine-mediated apoptosis involves changes in mitochondrial
membrane permeabilization and in the emergence of the active form of Bak. (A) TCERG1 knockdown
decreases the mitochondrial membrane potential dissipation caused by staurosporine. Control and
TCERG1-knockdown (KD) Jurkat cells were incubated without (-STAU) or with 0.5 μM staurosporine
(+STAU) for 1 h and stained with JC-1 dye. Green fluorescence was measured by flow cytometry, and the
data were analyzed using FlowJo software. The bar diagram shows the quantification of JC-1 monomers
from two independent experiments (means ± SEM). *, p < 0.05. (B) TCERG1mRNA interference decreases
the mitochondrial membrane potential dissipation caused by oxaliplatin in Jurkat cells. Control and
shTCERG1 Jurkat cells were incubated without (-OXALIP) or with 20 μM oxaliplatin (+OXALIP) for 18 h and
stained with JC-1 dye. Green fluorescence was measured by flow cytometry, and the data were analyzed
using CellQuest and GraphPad software. The bar diagram shows the quantification of JC-1 monomers from
two independent experiments (means ± SEM). **, p < 0.01. (C) Changes in Bak-associated fluorescence
were quantified by flow cytometry after intracellular staining with the Ab-1 antibody. (D and E) The release of
cytochrome c was analyzed by flow cytometry and immunofluorescence. The graphs show data from three
independent experiments (means ± SEM). *, p < 0.05, **, p < 0.01.
doi:10.1371/journal.pone.0139812.g005
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after staurosporine treatment (Fig 6A). Similarly, the overexpression of TCERG1 increased the
percentage of the sub-G1 cell population in the presence of staurosporine (Fig 6A). An inter-
pretation of these results is that the increase in the Bcl-xS isoform elicited by TCERG1 overex-
pression promoted apoptosis in response to staurosporine treatment. Consistent with this
hypothesis, the overexpression of Bcl-xS under TCERG1 depletion partially reversed the
decrease in apoptotic cells observed after apoptosis induction in the absence of TCERG1 (Fig
6B), suggesting that the effect observed after the knockdown of TCERG1 was partly due to the
reduction of the Bcl-xS isoform.
We next analyzed the protein expression levels using specific antibodies. We observed a
decrease in Bcl-xL in the control cells after staurosporine treatment (Fig 6C, lanes 1 and 2) that
was partially recovered in the TCERG1-knocked down cells (Fig 6C, lanes 3 and 4), supporting
the functional results for alternative splicing and apoptosis. Unfortunately, we could not detect
Bcl-xS with commercially available antibodies (data not shown). To lend specificity to these
results, we did not observe any difference in Bcl-2 expression between the control and
TCERG1-knocked down cells (Fig 6C). Together, these results suggest that TCERG1 depletion
counteracts staurosporine-induced apoptosis by favoring the Bcl-xL over the Bcl-xS isoform.
TCERG1 depletion decreases death receptor-mediated apoptosis
Apoptosis can also be triggered in a cell through the extrinsic or death receptor-mediated path-
way, which is initiated through the stimulation of trans-membrane cell receptors, such as the
Fas receptors, located on the cell membrane. To test whether TCERG1 affects the extrinsic apo-
ptosis pathway, we used the agonistic monoclonal anti-Fas/CD95 antibody to induce apoptosis.
The anti-Fas/CD95 antibody binds to the membrane receptor Fas (APO-1/CD95), mimicking
the endogenous interaction of the receptor with its Fas ligand (FasL) to induce programmed
cell death. Annexin-V binding assays revealed that after anti-Fas/CD95 treatment, the control
cells showed a higher apoptosis level compared to the TCERG1-knocked down cells (Fig 7A).
Under these conditions, we observed an increase in cell viability (Fig 7B) and a decrease in cas-
pase-3 activity (Fig 7C) upon TCERG1 depletion. The analysis of caspase-3 and PARP-1 cleav-
age by western blotting revealed that the expression level of both apoptotic markers was
significantly reduced in the TCERG1-knocked down cells upon apoptosis induction by the
anti-Fas/CD95 treatment (Fig 7D). However, no differences were observed in the level of Bcl-
xL protein between control and TCERG1 knockdown cells (Fig 7D), suggesting that the effect
of TCERG1 with regard to inhibiting Fas-mediated apoptosis does not occur through the regu-
lation of Bcl-x alternative splicing. To confirm the role of TCERG1 in the extrinsic apoptosis
pathway, we assessed the ΔCm by measuring mitochondrial cytochrome c release into the
cytoplasm upon apoptosis. In agreement with our previous data, we observed significantly
reduced cytochrome c release in TCERG1 knockdown cells upon apoptosis induction using the
anti-Fas/CD95 antibody (Fig 7E). These data confirm that TCERG1 is involved in the extrinsic
apoptosis pathway triggered by the binding of the agonist anti-Fas/CDK9 antibody to the Fas
receptor.
TCERG1 knockdown favors exon 6 skipping of Fas/CD95 mRNA
The above-mentioned results suggest that the mechanism by which TCERG1 depletion reduces
extrinsic apoptosis induction is different than that observed for the intrinsic pathway. Many
genes involved in the death-receptor apoptotic pathway are regulated through alternative splic-
ing [3]. One example is the human Fas gene. FasmRNA transcripts lacking exon 6 generate a
soluble receptor, which can inhibit Fas-mediated apoptosis [12] (Fig 8A). To study the function
of TCERG1 in the regulation of Fas alternative splicing, we analyzed the splicing pattern of the
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Fig 6. TCERG1’s effect on staurosporine-mediated apoptosis is caused by a change in the Bcl-xL/Bcl-
xS ratio. (A) Overexpression of Bcl-xS and TCERG1 favors staurosporine-induced apoptosis. Jurkat cells
were transiently transfected with an empty vector (control) or with Bcl-xS or TCERG1 expression plasmids
(Bcl-xS OE and TCERG1OE, respectively). Cells were treated with (+STAU) or without 0.025 μM
staurosporine (-STAU) for 1 h, and the cell cycle was then analyzed. The graph shows the percentage of cells
in sub-G1 phase from three independent experiments (means ± SEM). *, p < 0.05. (B) The transient
overexpression of Bcl-xS in TCERG1-knockdown cells increases the number of apoptotic cells. Control and
TCERG1-knockdown Jurkat cells were transiently transfected with an empty vector or a Bcl-xS expression
plasmid (TCERG1 KD + Bcl-xS OE) in the case of TCERG1-knockdown cells. The cells were treated with
(+STAU) or without 0.5 μM staurosporine (-STAU) for 1 h, and the cell cycle was then analyzed. The graph
represents the percentage of cells in sub-G1 phase, measured by flow cytometry, from three independent
experiments (means ± SEM). *, p < 0.05. (C) Depletion of TCERG1 decreases the level of Bcl-xL protein in
cells upon staurosporine treatment. Cell extracts from control and TCERG1 knockdown (KD) Jurkat cells with
(+STAU) or without treatment with 0.5 μM staurosporine (-STAU) for 1 h were analyzed by immunoblotting
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Fig 7. Effect of TCERG1 knockdown on Fas-mediated apoptosis. (A) TCERG1 knockdown reduces
annexin-V binding after the induction of Fas-mediated apoptosis. Control and TCERG1 knockdown (KD)
Jurkat cells were incubated with annexin-V and analyzed by flow cytometry in the absence (-) or presence (+)
of 50 ng/ml of anti-Fas/CD95 for 6 h. The bar graph shows the percentage of annexin-V positive cells from
three independent experiments (means ± SEM). *, p < 0.05. (B) TCERG1 knockdown recovers the loss in
cell viability induced by anti-Fas/CD95 treatment. Control and TCERG1 knockdown (KD) Jurkat cells were
incubated in the absence (-) or presence (+) of 50 ng/ml of anti-Fas/CD95 for 6 h. The percentage of viable
cells was measured by a luminometric assay. The bar graph shows data from four independent experiments
(means ± SEM). *, p < 0.05. (C) The activation of caspase-3 is impaired in TCERG1 knockdown Jurkat cells
after induction of the extrinsic apoptosis pathway. Caspase-3 activation was measured by
chemiluminescence in control and TCERG1 knockdown (KD) Jurkat cells treated with (+) or without (-) α-Fas/
CD95 at 50 ng/ml for 6 h. The bar diagram shows the fold activation from four independent experiments
(means ± SEM). Data obtained from cells without α-Fas/CD95 treatment were set as 1. *, p < 0.05. (D)
Analysis of TCERG1, PARP-1 cleavage (p89), procaspase-3 cleavage (precursor p35 and cleaved
fragments p20/p17), and Bcl-xL protein expression levels. Protein expression was analyzed by
immunoblotting using specific antibodies in protein extracts obtained from control and TCERG1 knockdown
Jurkat cells from the experiment described in panel C. ß-actin was used as a loading control. (E) TCERG1
knockdown decreases cytochrome c release from the mitochondria after Fas-mediated apoptosis induction.
Control and TCERG1 knockdown (KD) Jurkat cells were incubated in the absence (-) or presence (+) of 50
ng/ml of α-Fas/CD95 for 6 h, and the cytochrome c released was measured using specific antibodies by flow
cytometry. The bar graph shows data from two independent experiments and represents the percentage of
cytochrome translocated to the cytosol. **, p < 0.01.
doi:10.1371/journal.pone.0139812.g007
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endogenous Fas gene by semiquantitative RT-PCR upon TCERG1 knockdown. Under these
conditions, we observed a weak increase in exon 6 skipping (data not shown). To confirm this
result, we repeated the analysis by qPCR using primers that exclusively amplify the trans-mem-
brane receptor isoform. Consistent with the previous result, we observed that the absence of
TCERG1 promoted a slight but significant decrease of approximately 15–20% in the pro-apo-
ptotic isoform (Fig 8B). To show that more Fas transcript lacking exon 6 is produced after
TCERG1 knockdown, we performed the qPCR using primers that exclusively amplify the short
transcript isoform. We observed a significant increase in the short anti-apoptotic isoform of
approximately 25%, which corroborates the previous data using primers that exclusively
amplify the long pro-apoptotic isoform (Fig 8C). We conclude that TCERG1 regulates Fas
Fig 8. Regulation of Fas alternative splicing by TCERG1. (A) Schematic representation of the structure of
the Fas gene, with exons 5, 6, and 7 (boxes), introns (lines), and alternative splicing events (dotted lines). The
alternative Fas isoforms generated by the inclusion or skipping of exon 6 are indicated. The primers used for
conventional PCR are shown with black lines and for qPCR as black arrows (B) Analysis of endogenous Fas
alternative splicing in control and siTCERG1 HEK293T cells. After total RNA extraction, RT-qPCRwas
carried out using the primers indicated in the panel (black arrows) to amplify the long transmembrane Fas
isoform. The bar graph represents the percentage of exon 6 inclusion (means ± SEM). Data are from four
independent experiments. *, p < 0.05. (C) The same experimental procedures described in B were performed
using specific primers to amplify the short soluble Fas isoform. Data are from three independent experiments.
*, p < 0.05. (D) Analysis of caspase-8 activation in control and TCERG1 knockdown Jurkat cells incubated
without (-) or with (+) 50 ng/ml of α-Fas/CD95 for 6 h. Caspase-8 activity was measured by a
chemiluminescence assay. The bar graph represents the fold induction of caspase-8 activity under these
conditions (means ± SEM). Data are from three independent experiments. *, p < 0.05.
doi:10.1371/journal.pone.0139812.g008
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alternative splicing possibly through a mechanism involving exon definition. These results sug-
gest the possibility that TCERG1 regulates apoptosis through the extrinsic pathway by modu-
lating the Fas alternative splicing and therefore promoting the accumulation of a specific Fas
isoform. To test this hypothesis, we evaluated an event in the apoptosis cascade generated
immediately after Fas signaling induction: caspase-8 activation. Caspase-8 is an initiator cas-
pase activated from pro-caspase 8 by the death-inducing signaling complex (DISC) after FasL/
Fas interaction [59]. We observed that depletion of TCERG1 caused a significant and repro-
ducible decrease in caspase-8 activation after the induction of apoptosis with the anti-Fas/
CD95 antibody (Fig 8D), which is similar to the approximately 20% induction of the pro-apo-
ptotic isoform observed in the splicing experiments (Fig 8B). Taken together, the results indi-
cate than the effect of TCERG1 on extrinsic apoptosis is due, at least partially, to its effect on
the regulation of Fas alternative splicing.
Discussion
In this manuscript, we report that TCERG1-mediated Bcl-x alternative splicing affects cell apo-
ptosis. Our findings provide a functional link between the control of alternative splicing and
the molecular events leading to apoptosis.
The protein kinase inhibitor staurosporine induces a switch in the production of Bcl-x
toward the Bcl-xS isoform [28]. The Bcl-xS variant is a pro-apoptotic protein that antagonizes
the survival functions of Bcl-xL [60] and sensitizes cells to the apoptosis induced by several
agents [19]. Here, we provide evidence that a decrease in the intracellular level of TCERG1
affects the alternative splicing of Bcl-x toward the production of the anti-apoptotic Bcl-xL vari-
ant after staurosporine treatment. Using multiple experimental approaches, we showed that
the splicing activity of TCERG1 affected the induction of apoptosis. We also showed that up-
regulation of Bcl-xS expression increased sensitivity to the apoptotic stimulus and counteracted
the effect of TCERG1 depletion. Overall, our results indicate the ability of TCERG1 to alter the
splice site selection of a key apoptotic gene to regulate cell survival.
Staurosporine is an inhibitor of the PKC pathway that contributes to Bcl-x splicing regula-
tion through the SB1 regulatory element [28]. It has been postulated that a splicing repressor
present at a nearly limiting concentration binds to SB1 and down-regulates the production of
Bcl-xS. Thus, blocking the phosphorylation of this putative repressor would suppress its activity
and favor degradation of the proteasome-mediated repressor [51]. By stimulating the tran-
scriptional elongation of the Bcl-x gene, TCERG1 could reduce the time available for the
assembly and activity of this repressor at SB1, thus favoring the production of the Bcl-xS iso-
form [35]. If this mechanistic scenario is correct, it is possible that only the apoptotic inducers
affecting the activity of this splicing repressor would act in the TCERG1-mediated control of
apoptosis. The anticancer drug oxaliplatin favors the pro-apoptotic Bcl-xS variant through the
same SB1 element that receives signals from the PKC pathway, suggesting that the PKC path-
way and the DNA damage signaling route induced by oxaliplatin converge [50, 51]. Our results
showed reduced cell death and a higher ΔCm upon oxaliplatin treatment in Jurkat-shTCERG1
cells, whereas doxorubicin, which promotes apoptosis through a different route, showed no
effects on these cells. These data support the idea of staurosporine-dependent effects and sug-
gest a molecular scenario in which the activity of the SB1-binding repressor is being modified.
Our results also suggest a precise mechanism by which TCERG1 modulates the intrinsic
apoptosis pathway. Bak is a member of the Bcl-2 protein family that controls apoptosis by reg-
ulating the permeability of the mitochondrial outer membrane and release of cytochrome c
[61]. In healthy cells, Bak is blocked by several anti-apoptotic proteins, such as Bcl-x. Upon
induction of apoptosis, Bak undergoes a conformational change that results in the exposure of
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the amino-terminal region, the release of the anti-apoptotic related proteins, and the formation
of homo-oligomers. Our data suggest that upon staurosporine induction, the partial recovery
of the Bcl-xL level after TCERG1 knockdown increases the heterodimerization of Bak and Bcl-
xL, thus reducing the availability of the amino-terminus of Bak and preventing the initial step
of cytochrome c release under Bak-mediated mitochondrial apoptosis. Therefore, our data are
compatible with a model in which cell death is suppressed by the heterodimerization of Bak
and Bcl-xL and in which the dissociation of these proteins leads to mitochondrial permeabiliza-
tion and the release of proteins that participate in the execution of apoptosis. The precise
mechanism of TCERG1 action and the role of other Bcl-2 family members remain unknown.
TCERG1 also affects the extrinsic apoptotic pathway. The down-regulation of TCERG1
decreases the apoptosis induced by anti-Fas/CD95 treatment, though no differences were
observed in the Bcl-xL expression level. However, the depletion of TCERG1 provokes a
decrease in the pro-apoptotic Fas isoform that correlates with the decreased activity of caspase-
8, which is known to be the first step in the cascade of apoptosis events induced by Fas stimula-
tion. The effect in caspase-8 activation does not appear to be sufficient to explain the inhibition
of apoptosis observed in cells in which TCERG1 expression is reduced, indicating that later
events in the apoptosis cascade might be affected. We cannot discount that other genes impli-
cated in the death receptor pathway that are regulated by alternative splicing might be regu-
lated by TCERG1. For example, Bid, a member of the Bcl-2 family that is activated in response
to activation of cell surface death receptors [62], can be expressed in different isoforms that can
induce or inhibit apoptosis [63]. It would be interesting to determine whether TCERG1 regu-
lates the alternative splicing of Bid. In support of our data, TCERG1 has been recently identi-
fied as a regulator in Fas/CD95 alternative splicing using an automatized genome-wide siRNA
screening [64].
We have previously reported that TCERG1 could modulate the elongation rate of RNAPII
to relieve a putative polymerase pause site for proper pre-mRNA synthesis and processing
[35]. Recent studies suggest that pausing could act as a checkpoint to ensure the optimal activ-
ity of RNAPII during development, especially in highly regulated or inducible genes [65, 66].
This checkpoint could serve as a tool to unify responses to different signaling pathways or sti-
muli. The alternative splicing of multiple genes is altered in response to signaling pathways
[67]. In the case of the alternative splicing of Bcl-x, apoptosis is regulated by signals that include
the de novo synthesis of ceramide and phosphatase PP1 [31]. PKC inhibitors also alter Bcl-x
alternative splicing in healthy but not in oncogenic cells [28], and a signaling pathway through
PI3K is responsible for the changes in the Bcl-xL/Bcl-xS mRNA ratio in cancer tissues by affect-
ing the expression of the splicing factor SAP155 [68]. These data indicate that specific signaling
pathways regulate the alternative splicing of important apoptosis genes. TCER-1, the Caenor-
habditis elegans TCERG1 homolog, responds to reproductive signals and promotes the expres-
sion of a set of genes regulated by the conserved, life-extending transcription factor DAF-16/
FOXO [69]. An attractive possibility is that TCERG1 acts as a checkpoint in response to differ-
ent stimuli, such as apoptosis induction, to control transcription elongation, alternative splic-
ing, or other post-transcriptional steps [70].
The physiological relevance of the Bcl-xL/Bcl-xS mRNA ratio has been demonstrated in
multiple studies [32, 68, 71, 72]. In addition, many cancer cells overexpress Bcl-xL, and this iso-
form cooperates with Myc to promote oncogenic transformation by blocking Myc-induced
apoptosis [73]. Fas receptor ratios are also important for development or disease, and the dif-
ferential expression of alternatively spliced Fas mRNA isoforms is associated with lymphocyte
activation, autoimmune lymphoproliferative syndrome, systemic lupus erythematosus, and
systemic sclerosis [74–77]. Hence, manipulation of the ratio of alternatively spliced mRNA iso-
forms of genes is a promising strategy to sensitize the cells to therapeutic agents. The results
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described in the present study suggest that the regulation of the alternative splicing of the Bcl-x
and Fas apoptotic genes by TCERG1 is a relevant regulatory pathway in modulating apoptotic
responses to sensitize a cell to apoptotic inductors.
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